<DOC>
	<DOCNO>NCT00380692</DOCNO>
	<brief_summary>The purpose study determine whether atomoxetine effective reduce ADHD ( Attention Deficit/Hyperactivity Disorder ) symptoms child adolescent ASD ( Autism Spectrum Disorder ) .</brief_summary>
	<brief_title>Atomoxetine Versus Placebo Symptoms Attention-Deficit/Hyperactivity Disorder ( ADHD ) Children Adolescents With Autism Spectrum Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria ( important ) : ASD ( autistic disorder Asperger 's disorder Pervasive Developmental Disorder Not Otherwise Specified [ PDD NOS ] ) Criteria A D AttentionDeficit/Hyperactivity Disorder ( ADHD ) At least 1.5 standard deviation age norm diagnostic subtype use publish norm ADHD Rating ScaleIVParent Version Intelligence quotient ( IQ ) score &gt; 60 Exclusion Criteria ( important ) : weight 20 kg Patients meet Diagnostic Statistical Manual Mental Disorders Fourth Edition , Text Revision ( DSMIVTR ) criteria ASD Autistic Disorder , PDDNOS Asperger 's Disorder ; history Bipolar I II disorder , schizophrenia , another psychotic disorder , substance abuse ; Have significant medical condition heart disease , hypertension , liver renal failure , pulmonary disease , seizure disorder identify history , physical examination , laboratory test ; Patients take ( currently take ) anticonvulsant seizure control . patient serious suicidal risk . Contraindication use atomoxetine Patients investigator 's judgment likely need psychotropic medication apart drug . Patients time Study Period II likely begin structure psychotherapy , likely require hospitalization ( i.e . inpatient treatment ) likely dismissed inpatient treatment . Psychotherapy ( include hospitalization ) initiate least 2 month prior study participation acceptable ; however , study participation begin , Study Period III supportive educational therapy permit .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>